https://www.pharmaradar360.com/article/aspen-positions-itself-as-key-african-supplier-of-merck-hiv-pill-e918a9517c3dabd3Pharma Surgeen2026-07-26T15:19:04.000ZAspen positions itself as key African supplier of Merck HIV pillhttps://www.pharmaradar360.com/article/icar-dg-balanced-biotech-regulation-for-india-s-farm-sector-e1611c1f35544baaPharma Surgeen2026-07-26T15:15:50.000ZICAR DG: Balanced Biotech Regulation for India''s Farm Sectorhttps://www.pharmaradar360.com/article/orange-juice-residues-contain-hesperidin-limonene-valencene-and-other-substances-cabeb4fb3777360fPharma Surgeen2026-07-26T14:48:00.000ZOrange juice residues contain hesperidin, limonene, valencene, and other substances that can become a source of valuable compounds for the pharmaceutical and cosmetic industries.https://www.pharmaradar360.com/article/egypt-to-link-drug-prices-to-exchange-rate-and-inflation-4332ff621be073f8Pharma Surgeen2026-07-26T14:38:15.000ZEgypt to link drug prices to exchange rate and inflationhttps://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-l-a-biotech-exec-9e9c1df77595c320Pharma Surgeen2026-07-26T13:18:31.000ZFugitive doctor on run for 21 years was living as L.A. biotech exechttps://www.pharmaradar360.com/article/tiansheng-pharmaceutical-group-co-ltd-class-a-revenue-breakdown-szse-002872-b10d400a05388157Pharma Surgeen2026-07-26T12:10:14.000ZTiansheng Pharmaceutical Group Co. Ltd. Class A Revenue Breakdown – SZSE:002872https://www.pharmaradar360.com/article/labturbo-biotech-corporation-revenue-breakdown-tpex-7725-f60e1b22a23e49fePharma Surgeen2026-07-26T11:33:30.000ZLabTurbo Biotech Corporation Revenue Breakdown – TPEX:7725https://www.pharmaradar360.com/article/arrowhead-pharmaceuticals-arwr-challenges-ionis-ions-with-strong-phase-3-data-in-98ad224f6c6f5b49Pharma Surgeen2026-07-26T10:20:24.000ZArrowhead Pharmaceuticals (ARWR) Challenges Ionis (IONS) With Strong Phase 3 Data In Hypertriglyceridemia Racehttps://www.pharmaradar360.com/article/the-key-to-thriving-in-pharmaceutical-sciences-d8a7d0f5a906fca7Pharma Surgeen2026-07-26T10:18:03.000ZThe Key to Thriving in Pharmaceutical Scienceshttps://www.pharmaradar360.com/article/jyong-biotech-ltd-mens-risk-assessment-volatility-financial-risk-investment-risk-8f0d2ccb119d3c8bPharma Surgeen2026-07-26T10:15:56.000ZJyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Riskhttps://www.pharmaradar360.com/article/charmacy-pharmaceutical-co-ltd-class-h-revenue-breakdown-hkex-2289-7db22e201f9c79c1Pharma Surgeen2026-07-26T09:55:15.000ZCharmacy Pharmaceutical Co., Ltd. Class H Revenue Breakdown – HKEX:2289https://www.pharmaradar360.com/article/amgen-ecovation-how-amgen-builds-sustainability-into-biotech-52bd0d751ed179dcPharma Surgeen2026-07-26T09:47:55.000ZAmgen Ecovation®: How Amgen Builds Sustainability Into Biotechhttps://www.pharmaradar360.com/article/how-polpharma-plans-to-build-a-cee-pharmaceutical-platform-223580291ad8e003Pharma Surgeen2026-07-26T09:43:00.000ZHow Polpharma plans to build a CEE pharmaceutical platformhttps://www.pharmaradar360.com/article/us-tariff-proposal-wake-up-call-for-indian-pharma-to-diversify-innovate-experts-cb7b21d166c4fa45Pharma Surgeen2026-07-26T09:32:10.000ZUS tariff proposal wake-up call for Indian pharma to diversify, innovate: Expertshttps://www.pharmaradar360.com/article/innovative-drug-sector-strong-rally-rebound-or-full-reversal-latest-in-depth-fun-ecc93d1767478317Pharma Surgeen2026-07-26T09:22:59.000ZInnovative Drug Sector Strong Rally: Rebound or Full Reversal? Latest In-Depth Fund Manager Judgmentshttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-limited-revenue-breakdown-nse-sunpharma-6cf501cd1c90db56Pharma Surgeen2026-07-26T09:14:11.000ZSun Pharmaceutical Industries Limited Revenue Breakdown – NSE:SUNPHARMAhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-reports-new-phase-3-psoriasis-data-is-the-10-disc-d7b38acc3099460aPharma Surgeen2026-07-26T09:09:17.000ZTakeda Pharmaceutical (TSE:4502) Reports New Phase 3 Psoriasis Data, Is The 10% Discount Enough?https://www.pharmaradar360.com/article/china-pharmaceutical-drying-equipment-market-analysis-forecast-size-trends-and-i-0e77c7a99dbe731aPharma Surgeen2026-07-26T09:05:02.000ZChina Pharmaceutical Drying Equipment - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/etf-showdown-xbi-vs-pbe-which-biotech-fund-wins-eaa983bcff893e4cPharma Surgeen2026-07-26T08:40:15.000ZETF Showdown: XBI vs PBE, Which Biotech Fund Wins?https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-tev-q4-2025-earnings-report-results-call-5ab93d80312a256ePharma Surgeen2026-07-26T08:39:35.000ZTeva Pharmaceutical Industries Limited (TEV) Q4 2025 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-s-a-just-missed-eps-by-11-here-s-what-analysts-think-wi-92bbdbf832fc8512Pharma Surgeen2026-07-26T08:27:42.000ZSartorius Stedim Biotech S.A. Just Missed EPS By 11%: Here's What Analysts Think Will Happen Nexthttps://www.pharmaradar360.com/article/tkph4770188-bond-risk-profile-195a5bfa43a80067Pharma Surgeen2026-07-26T08:02:28.000ZTKPH4770188 Bond Risk Profilehttps://www.pharmaradar360.com/article/arrowstreet-capital-limited-partnership-purchases-210-112-shares-of-west-pharmac-836348f19fa38c05Pharma Surgeen2026-07-26T07:51:12.000ZArrowstreet Capital Limited Partnership Purchases 210,112 Shares of West Pharmaceutical Services, Inc. $WSThttps://www.pharmaradar360.com/article/consun-pharmaceutical-group-ltd-revenue-breakdown-hkex-1681-d6bd96f03f426e78Pharma Surgeen2026-07-26T07:50:51.000ZConsun Pharmaceutical Group Ltd. Revenue Breakdown – HKEX:1681https://www.pharmaradar360.com/article/orforglipron-news-foundayo-fda-approved-for-weight-loss-4438c6075538dfbaPharma Surgeen2026-07-26T07:41:10.000ZOrforglipron News: Foundayo FDA Approved for Weight losshttps://www.pharmaradar360.com/article/cachet-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-002462-1d81d5b6ce509a8ePharma Surgeen2026-07-26T07:29:33.000ZCachet Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:002462https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-shares-acquired-by-bank-of-nova-scotia-ba5c1d35a8262d94Pharma Surgeen2026-07-26T07:24:34.000ZWest Pharmaceutical Services, Inc. $WST Shares Acquired by Bank of Nova Scotiahttps://www.pharmaradar360.com/article/whan-in-pharmaceutical-co-ltd-revenue-breakdown-krx-016580-80962f1ca25cf58ePharma Surgeen2026-07-26T07:18:37.000ZWhan In Pharmaceutical Co., Ltd. Revenue Breakdown – KRX:016580https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhuhai-rundu-pharmaceutical-co-ltd-class-a-s-54c62203ea9223e4Pharma Surgeen2026-07-26T07:12:49.000ZEnterprise value to EBIT forward of Zhuhai Rundu Pharmaceutical Co. Ltd. Class A – SZSE:002923https://www.pharmaradar360.com/article/the-litmus-study-just-changed-how-you-should-design-your-masld-trial-endpoints-3bb9c82f814d1d09Pharma Surgeen2026-07-26T06:40:51.000ZThe LITMUS Study Just Changed How You Should Design Your MASLD Trial Endpointshttps://www.pharmaradar360.com/article/tak-takeda-pharmaceutical-co-ltd-price-17-240-chg-0-435-40fa51df2325f746Pharma Surgeen2026-07-26T06:22:22.000ZTAK|Takeda Pharmaceutical Co Ltd|Price:17.240|Chg%:+0.435https://www.pharmaradar360.com/article/west-pharmaceutical-stock-holds-recent-gains-as-investors-weigh-steady-growth-an-e12f9c65a03b6e5ePharma Surgeen2026-07-26T05:18:59.000ZWest Pharmaceutical stock holds recent gains as investors weigh steady growth and guidancehttps://www.pharmaradar360.com/article/withus-pharmaceutical-co-ltd-revenue-breakdown-krx-330350-9075c0f60a76345fPharma Surgeen2026-07-26T05:16:26.000ZWITHUS PHARMACEUTICAL Co., Ltd. Revenue Breakdown – KRX:330350https://www.pharmaradar360.com/article/price-to-sales-forward-of-hunan-hansen-pharmaceutical-co-ltd-class-a-szse-002412-bdb55eb1e1cb20d4Pharma Surgeen2026-07-26T05:13:15.000ZPrice to sales forward of Hunan Hansen Pharmaceutical Co., Ltd. Class A – SZSE:002412https://www.pharmaradar360.com/article/west-pharmaceutical-wst-signs-decade-long-daikyo-distribution-deal-beyond-japan-ec1bad39eeaf22a0Pharma Surgeen2026-07-26T05:12:00.000ZWest Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japanhttps://www.pharmaradar360.com/article/outsourcing-formulation-activities-may-advance-drug-development-5944d75d5ad4da59Pharma Surgeen2026-07-26T04:57:04.000ZOutsourcing Formulation Activities May Advance Drug Developmenthttps://www.pharmaradar360.com/article/collegium-pharmaceutical-inc-revenue-breakdown-boats-coll-424549d041650b82Pharma Surgeen2026-07-26T04:31:37.000ZCollegium Pharmaceutical, Inc. Revenue Breakdown – BOATS:COLLhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-zhejiang-hisoar-pharmaceutical-co-ltd-clas-26af6908b515f4f1Pharma Surgeen2026-07-26T04:30:57.000ZEnterprise value to EBITDA forward of Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A – SZSE:002099https://www.pharmaradar360.com/article/rare-ultragenyx-pharmaceutical-inc-price-26-900-chg-0-120-4ba2abef33a7803dPharma Surgeen2026-07-26T04:16:59.000ZRARE|Ultragenyx Pharmaceutical Inc|Price:26.900|Chg%:-0.120https://www.pharmaradar360.com/article/livzon-pharmaceutical-group-inc-class-h-revenue-breakdown-lsx-a1xcaw-7244ffcfab0f891dPharma Surgeen2026-07-26T03:51:04.000ZLivzon Pharmaceutical Group Inc Class H Revenue Breakdown – LSX:A1XCAWhttps://www.pharmaradar360.com/article/south-korea-s-largest-ever-pharmaceutical-industry-m-a-deal-a-historic-milestone-f372a29e286e1e11Pharma Surgeen2026-07-26T03:12:25.000ZSouth Korea's Largest-Ever Pharmaceutical Industry M&A Deal: A Historic Milestone in the Makinghttps://www.pharmaradar360.com/article/central-pharmaceutical-cpc1-jsc-revenue-breakdown-upcom-dp1-219f0e03e74813aaPharma Surgeen2026-07-26T01:12:36.000ZCentral Pharmaceutical CPC1.JSC Revenue Breakdown – UPCOM:DP1https://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-advances-lead-bitac-r-t-cell-engager-program-with-cel-a351c282a2ef6f46Pharma Surgeen2026-07-26T01:03:15.000ZVERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnershiphttps://www.pharmaradar360.com/article/prnaf-sec-filings-alterity-therapeutics-ltd-10-k-10-q-8-k-forms-32e0d2dcee460616Pharma Surgeen2026-07-26T00:45:27.000ZPRNAF SEC Filings - ALTERITY THERAPEUTICS LTD 10-K, 10-Q, 8-K Formshttps://www.pharmaradar360.com/article/dwwd-etf-profile-dividends-returns-mun-dwwd-7cf3550f22e46273Pharma Surgeen2026-07-26T00:31:09.000ZDWWD ETF Profile: Dividends, Returns (MUN:DWWD)https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-41d6cbd2bc4c8880Pharma Surgeen2026-07-26T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-6e0fda0dcf131e47Pharma Surgeen2026-07-26T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-90077d3c165d4bfePharma Surgeen2026-07-26T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-48d343fa67eee304Pharma Surgeen2026-07-26T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-167c1bfd0be60c27Pharma Surgeen2026-07-26T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-4fb27967e93f1d55Pharma Surgeen2026-07-26T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-9d3e0ed602c0c53fPharma Surgeen2026-07-26T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-21cfb0ea7b6c71b1Pharma Surgeen2026-07-26T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-f2df55e6e9e48854Pharma Surgeen2026-07-26T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-f06914ffb3c89704Pharma Surgeen2026-07-26T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-747ec854e9fbb6e6Pharma Surgeen2026-07-26T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-0a26dc6ca3046f5bPharma Surgeen2026-07-26T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-3ddb7d17113efd90Pharma Surgeen2026-07-26T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-3fc4246a23de751ePharma Surgeen2026-07-26T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/clinical-outcomes-following-definitive-concurrent-chemoradiotherapy-in-patients-fc27cf47c83bbb48Pharma Surgeen2026-07-26T00:00:00.000ZClinical Outcomes Following Definitive Concurrent Chemoradiotherapy in Patients With International Federation of Gynecology and Obstetrics (FIGO) Stage IB-IVA Carcinoma of the Cervixhttps://www.pharmaradar360.com/article/orchestrating-modelling-amp-simulation-of-pharmaceutical-production-processes-vi-1d6370a3880d7533Pharma Surgeen2026-07-26T00:00:00.000ZOrchestrating Modelling &amp; Simulation of Pharmaceutical Production Processes Via Large Language Modelshttps://www.pharmaradar360.com/article/role-of-multivariate-data-analyses-in-formulation-and-process-development-of-ora-3c3510df6a686904Pharma Surgeen2026-07-26T00:00:00.000ZRole of Multivariate Data Analyses In Formulation and Process Development of Oral Solid Drug Products: Encapsulation Case Studieshttps://www.pharmaradar360.com/article/a-decade-of-digitizing-pharmaceutical-manufacturing-at-jnj-lessons-learned-and-f-754cecd21ba9815dPharma Surgeen2026-07-26T00:00:00.000ZA Decade of Digitizing Pharmaceutical Manufacturing at JnJ: Lessons Learned and Future Directionshttps://www.pharmaradar360.com/article/pneumobilia-a-clinical-perspective-on-interpretation-and-management-7736a72acaa2c5e5Pharma Surgeen2026-07-26T00:00:00.000ZPneumobilia: A Clinical Perspective on Interpretation and Managementhttps://www.pharmaradar360.com/article/non-steroidal-anti-inflammatory-drug-use-and-the-risk-of-incident-heart-failure-2ea21dcfaa109ec9Pharma Surgeen2026-07-26T00:00:00.000ZNon-Steroidal Anti-Inflammatory Drug Use and the Risk of Incident Heart Failure in Patients with Type 2 Diabetes Mellitus: A Systematic Reviewhttps://www.pharmaradar360.com/article/evaluation-of-drug-utilization-patterns-using-who-indicators-in-patients-with-en-d0358e2f460d6b7cPharma Surgeen2026-07-26T00:00:00.000ZEvaluation of Drug Utilization Patterns Using WHO Indicators in Patients with End-Stage Chronic Kidney Disease: A Cross-Sectional Study in Kirkuk, Iraqhttps://www.pharmaradar360.com/article/lyme-carditis-with-pericarditis-a-review-of-clinical-cases-47c7209d7e11ae42Pharma Surgeen2026-07-26T00:00:00.000ZLyme carditis with pericarditis: A review of clinical caseshttps://www.pharmaradar360.com/article/mesenchymal-stem-cell-derived-extracellular-vesicles-as-next-generation-drug-del-a2ebad1887074d8ePharma Surgeen2026-07-26T00:00:00.000ZMesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platformshttps://www.pharmaradar360.com/article/clinical-significance-of-mesenchymal-stem-cells-exosomal-micrornas-in-predicting-d43f76f9e474ca1dPharma Surgeen2026-07-26T00:00:00.000ZClinical significance of mesenchymal stem cells exosomal microRNAs in predicting prognosis and inflammatory response of esophageal cancerhttps://www.pharmaradar360.com/article/mechanistic-insights-into-honeybee-propolis-as-a-natural-modulator-of-inflammati-6f3ef953864efabfPharma Surgeen2026-07-26T00:00:00.000ZMechanistic Insights into Honeybee Propolis as a Natural Modulator of Inflammation and Oxidative Stress: A Narrative Reviewhttps://www.pharmaradar360.com/article/in-vitro-evaluation-of-antioxidant-activity-and-tyrosinase-inhibition-of-syzygiu-0600f715b3aa7078Pharma Surgeen2026-07-26T00:00:00.000ZIn Vitro Evaluation of Antioxidant Activity and Tyrosinase Inhibition of Syzygium polyanthum Extracthttps://www.pharmaradar360.com/article/prunasin-alleviates-ogd-r-induced-injury-in-h9c2-cardiomyocytes-via-src-egfr-akt-44fe2006be98e1e1Pharma Surgeen2026-07-26T00:00:00.000ZPrunasin alleviates OGD/R-induced injury in H9c2 cardiomyocytes via SRC/EGFR-AKT-FoxO-mediated mitochondrial quality controlhttps://www.pharmaradar360.com/article/astragaloside-iv-attenuates-high-glucose-induced-podocyte-ferroptosis-via-the-gs-26666fa473cf2721Pharma Surgeen2026-07-26T00:00:00.000ZAstragaloside IV attenuates high glucose-induced podocyte ferroptosis via the GSK3?/Nrf2/GPX4 pathwayhttps://www.pharmaradar360.com/article/duo-nang-decoction-enhances-endometrial-receptivity-in-pcos-rats-by-upregulating-cc0bf35c2fb30077Pharma Surgeen2026-07-26T00:00:00.000ZDuo Nang Decoction enhances endometrial receptivity in PCOS rats by upregulating caveolin-1 expressionhttps://www.pharmaradar360.com/article/clinical-profiles-risk-factors-and-management-outcomes-of-ectopic-pregnancy-atte-4945fc67accc52eePharma Surgeen2026-07-26T00:00:00.000ZClinical Profiles, Risk Factors and Management Outcomes of Ectopic Pregnancy attended at a Tertiary Care Hospital in Bangladeshhttps://www.pharmaradar360.com/article/clinical-characteristics-precipitating-factors-in-hospital-management-and-30-day-3d3046bdeeb3564bPharma Surgeen2026-07-26T00:00:00.000ZClinical Characteristics, Precipitating Factors, In-Hospital Management, and 30-Day Outcomes of Patients Hospitalized with Acute Decompensated Heart Failure: A Single-Center Study from Vietnamhttps://www.pharmaradar360.com/article/overlapping-pathological-features-of-alzheimer-s-and-parkinson-s-diseases-clinic-f5b28d38a424e95ePharma Surgeen2026-07-26T00:00:00.000ZOverlapping pathological features of Alzheimer’s and Parkinson’s diseases: Clinical implications and future directions for improving diagnostic precisionhttps://www.pharmaradar360.com/article/herbal-drug-adulteration-a-threat-to-safety-efficacy-and-global-herbal-trade-22fef03aa8dbb793Pharma Surgeen2026-07-26T00:00:00.000ZHerbal Drug Adulteration: A Threat to Safety, Efficacy, and Global Herbal Tradehttps://www.pharmaradar360.com/article/intradural-extramedullary-formation-in-a-pregnant-woman-a-clinical-case-590b68942c72cda7Pharma Surgeen2026-07-26T00:00:00.000ZIntradural extramedullary formation in a pregnant woman: a clinical casehttps://www.pharmaradar360.com/article/lhermitte-duclos-disease-rare-clinical-case-9ea7e124b3e8988fPharma Surgeen2026-07-26T00:00:00.000ZLhermitte-Duclos disease: rare clinical casehttps://www.pharmaradar360.com/article/psychogenic-non-epileptic-seizures-in-pediatric-neurosurgical-patients-with-drug-958afa8bfa952872Pharma Surgeen2026-07-26T00:00:00.000ZPsychogenic non-epileptic seizures in pediatric neurosurgical patients with drug-resistant epilepsyhttps://www.pharmaradar360.com/article/feasibility-of-using-a-patient-portal-to-recruit-latino-adults-into-a-smoking-ce-50cd680715f04782Pharma Surgeen2026-07-26T00:00:00.000ZFeasibility of using a patient portal to recruit Latino adults into a smoking cessation and physical activity randomized clinical trial: A secondary analysishttps://www.pharmaradar360.com/article/correction-to-spontaneous-fracture-of-a-titanium-mesh-cranioplasty-implant-in-a-fa09bf0804c10563Pharma Surgeen2026-07-26T00:00:00.000ZCorrection to “Spontaneous fracture of a titanium mesh cranioplasty implant in a child: A case report”https://www.pharmaradar360.com/article/fish-oil-emulsion-for-reversal-of-intestinal-failure-associated-liver-disease-in-e8821df9bdfb2f68Pharma Surgeen2026-07-26T00:00:00.000ZFish oil emulsion for reversal of intestinal failure-associated liver disease in preterm infants: Three case reports and review of literaturehttps://www.pharmaradar360.com/article/decoding-the-glycemic-paradox-the-imperative-for-frailty-centered-inpatient-diab-811e9a73b5acecddPharma Surgeen2026-07-26T00:00:00.000ZDecoding the glycemic paradox: The imperative for frailty-centered inpatient diabetes carehttps://www.pharmaradar360.com/article/dickkopf-1-in-rheumatoid-arthritis-mechanistic-insights-imaging-associations-and-deabfa656ba9e7c3Pharma Surgeen2026-07-26T00:00:00.000ZDickkopf-1 in rheumatoid arthritis: Mechanistic insights, imaging associations, and emerging therapeutic strategieshttps://www.pharmaradar360.com/article/wilson-s-disease-in-children-recent-update-on-pathophysiology-and-management-b31544a43d24167dPharma Surgeen2026-07-26T00:00:00.000ZWilson’s disease in children: Recent update on pathophysiology and managementhttps://www.pharmaradar360.com/article/limited-transscleral-cyclophotocoagulation-for-silicone-oil-induced-glaucoma-in-20bd908c2bafaafcPharma Surgeen2026-07-26T00:00:00.000ZLimited transscleral cyclophotocoagulation for silicone oil-induced glaucoma in eyes with good visual potentialhttps://www.pharmaradar360.com/article/aspiration-of-a-metallic-crowned-tooth-in-the-left-main-bronchus-in-a-neurocriti-7586522aed69a82dPharma Surgeen2026-07-26T00:00:00.000ZAspiration of a metallic-crowned tooth in the left main bronchus in a neurocritical patient: A case reporthttps://www.pharmaradar360.com/article/rectal-mantle-cell-lymphoma-endoscopically-mimicking-ulcerative-proctitis-a-case-d6737d164ffab75cPharma Surgeen2026-07-26T00:00:00.000ZRectal mantle cell lymphoma endoscopically mimicking ulcerative proctitis: A case reporthttps://www.pharmaradar360.com/article/phase-ii-multicenter-clinical-trial-of-intraoperative-molecular-imaging-with-abe-8c9457100c005e40Pharma Surgeen2026-07-26T00:00:00.000ZPhase II Multicenter Clinical Trial of Intraoperative Molecular Imaging with Abenacianine During Lung Cancer Surgeryhttps://www.pharmaradar360.com/article/early-prediction-of-intensive-care-unit-acquired-weakness-using-quadriceps-ultra-bd1ace49132c8a96Pharma Surgeen2026-07-26T00:00:00.000ZEarly prediction of intensive care unit-acquired weakness using quadriceps ultrasound and routine clinical variables: development and temporal validation of a prospective multicentre machine-learning modelhttps://www.pharmaradar360.com/article/factors-influencing-the-acceptability-of-remote-multicomponent-rehabilitation-ve-b24053bd3dde07c0Pharma Surgeen2026-07-26T00:00:00.000ZFactors influencing the acceptability of remote multicomponent rehabilitation versus standard care following critical illness: a theory-informed qualitative study embedded within the iRehab trialhttps://www.pharmaradar360.com/article/proteomic-insights-in-sepsis-advancing-diagnosis-therapeutic-targets-and-the-pat-5c0de7ea8a9d415bPharma Surgeen2026-07-26T00:00:00.000ZProteomic insights in sepsis: advancing diagnosis, therapeutic targets, and the path to precision medicinehttps://www.pharmaradar360.com/article/life-stage-specific-hematological-profiles-in-yellow-mealworm-beetles-i-tenebrio-5278bb9c0d386167Pharma Surgeen2026-07-26T00:00:00.000ZLife‐Stage–Specific Hematological Profiles in Yellow Mealworm Beetles ( <i>Tenebrio molitor</i> ): Reference Intervals and Hemocyte Characterizationhttps://www.pharmaradar360.com/article/the-forgotten-history-of-semi-implanted-radiofrequency-and-inductive-powered-car-eaec77e0c590452fPharma Surgeen2026-07-26T00:00:00.000ZThe Forgotten History of Semi‐Implanted Radiofrequency‐ and Inductive‐Powered Cardiac Pacing Systemshttps://www.pharmaradar360.com/article/contact-index-for-pulseselect-catheter-apposition-validation-by-transesophageal-76a053877d9506e6Pharma Surgeen2026-07-26T00:00:00.000ZContact Index for PulseSelect Catheter Apposition: Validation by Transesophageal Echocardiographyhttps://www.pharmaradar360.com/article/variability-in-pacemaker-battery-estimates-and-performance-0efeb3542e7cf41ePharma Surgeen2026-07-26T00:00:00.000ZVariability in Pacemaker Battery Estimates and Performancehttps://www.pharmaradar360.com/article/anterior-versus-lateral-posterolateral-left-ventricular-lead-position-in-crt-a-s-57cf18369d46f4c3Pharma Surgeen2026-07-26T00:00:00.000ZAnterior Versus Lateral/Posterolateral Left Ventricular Lead Position in CRT: A Systematic Review and Meta‐Analysishttps://www.pharmaradar360.com/article/development-of-an-evaluation-framework-for-the-integration-of-clinical-and-preve-cda30125e9e521ebPharma Surgeen2026-07-26T00:00:00.000ZDevelopment of an Evaluation Framework for the Integration of Clinical and Preventive Medicine in Traditional Chinese Medicine: Using a DELPHI‐AHP Approachhttps://www.pharmaradar360.com/article/sequential-screening-as-diagnostic-filtering-or-substitution-a-bayesian-cost-mod-c80e8434982429f6Pharma Surgeen2026-07-26T00:00:00.000ZSequential Screening as Diagnostic Filtering or Substitution: A Bayesian Cost Model of Screening as a Function of Prevalencehttps://www.pharmaradar360.com/article/safety-and-pharmacokinetics-of-olamkicept-doses-up-to-2400-mg-in-healthy-japanes-96fc3b68e6690fbfPharma Surgeen2026-07-26T00:00:00.000ZSafety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trialhttps://www.pharmaradar360.com/article/letter-interpretation-of-cognitive-and-clinical-outcomes-in-the-randomized-trial-82c2f36988334baaPharma Surgeen2026-07-26T00:00:00.000ZLetter: Interpretation of Cognitive and Clinical Outcomes in the Randomized Trial of Rifaximin for Covert Hepatic Encephalopathy. Authors' Replyhttps://www.pharmaradar360.com/article/effectiveness-of-an-interdisciplinary-integrated-care-model-on-perioperative-out-7e7cf0f4a631ecccPharma Surgeen2026-07-26T00:00:00.000ZEffectiveness of an Interdisciplinary Integrated Care Model on Perioperative Outcomes in Patients Undergoing Lung Cancer Surgery: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/dose-intensity-and-clinical-outcomes-across-age-groups-in-high-grade-osteosarcom-d1f848c44c443a56Pharma Surgeen2026-07-26T00:00:00.000ZDose intensity and clinical outcomes across age groups in high-grade osteosarcoma treated with methotrexate, adriamycin, and cisplatin therapyhttps://www.pharmaradar360.com/article/great-obstetrical-syndromes-new-insights-into-progesterone-s-role-and-clinical-i-e1618b37d20c2c1bPharma Surgeen2026-07-26T00:00:00.000ZGreat obstetrical syndromes: new insights into progesterone’s role and clinical implicationshttps://www.pharmaradar360.com/article/comparative-efficacy-of-an-8-week-core-stability-program-versus-foot-ankle-stren-baf6caa2c3b11312Pharma Surgeen2026-07-26T00:00:00.000ZComparative efficacy of an 8-week core stability program versus foot-ankle strengthening on pain, function, and distal structural parameters in individuals with knee osteoarthritis: a randomized controlled trialhttps://www.pharmaradar360.com/article/could-the-geriatric-mobile-team-trial-germot-inclusion-criteria-be-a-pragmatic-a-1002daeb8caebe6dPharma Surgeen2026-07-26T00:00:00.000ZCould the Geriatric Mobile Team trial (GerMoT) inclusion criteria be a pragmatic approach to identifying older adults who may be a relevant target group for integrated care interventions?https://www.pharmaradar360.com/article/beyond-drug-discontinuation-and-prolonged-fasting-gastric-ultrasound-as-a-third-e00a7d01cbefc931Pharma Surgeen2026-07-26T00:00:00.000ZBeyond drug discontinuation and prolonged fasting: gastric ultrasound as a third option for patients taking GLP-1 receptor agonistshttps://www.pharmaradar360.com/article/pharmacometric-targets-during-anti-tnf-induction-and-their-association-with-deep-4f7b3c6a87bcba4dPharma Surgeen2026-07-26T00:00:00.000ZPharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Diseasehttps://www.pharmaradar360.com/article/effect-of-hepatic-impairment-on-the-pharmacokinetics-of-single-dose-viloxazine-e-8ab5ef50b5910335Pharma Surgeen2026-07-26T00:00:00.000ZEffect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree®) in Adultshttps://www.pharmaradar360.com/article/early-warning-and-behavioural-intervention-on-the-cardiovascular-disease-risk-in-0bfa413e61e44dbcPharma Surgeen2026-07-26T00:00:00.000ZEarly Warning and Behavioural Intervention on the Cardiovascular Disease Risk in People Living with HIV: A Multicentre Non-Randomized Controlled Trialhttps://www.pharmaradar360.com/article/sustained-normalization-of-hydrogen-positive-small-intestinal-bacterial-overgrow-d139500d62dddc7aPharma Surgeen2026-07-26T00:00:00.000ZSustained normalization of hydrogen-positive small intestinal bacterial overgrowth after polyethylene glycol bowel preparationhttps://www.pharmaradar360.com/article/successful-staged-endoscopic-treatment-of-multiple-gastrointestinal-varices-caus-435ec5fbaa32216aPharma Surgeen2026-07-26T00:00:00.000ZSuccessful staged endoscopic treatment of multiple gastrointestinal varices caused by oxaliplatin-induced sinusoidal obstruction syndromehttps://www.pharmaradar360.com/article/multimodal-approach-enables-r0-resection-in-advanced-gastric-adenocarcinoma-with-5ba1a7583d499338Pharma Surgeen2026-07-26T00:00:00.000ZMultimodal approach enables R0 resection in advanced gastric adenocarcinoma with enteroblastic differentiation complicated by portal vein tumor thrombushttps://www.pharmaradar360.com/article/successful-transition-to-mirikizumab-following-hepatic-abscess-during-adalimumab-a6002f6c7debba57Pharma Surgeen2026-07-26T00:00:00.000ZSuccessful transition to mirikizumab following hepatic abscess during adalimumab therapy in a patient with ulcerative colitishttps://www.pharmaradar360.com/article/adjuvant-immunotherapy-in-resected-non-small-cell-lung-cancer-harboring-oncogeni-32bc35898e96c9ffPharma Surgeen2026-07-26T00:00:00.000ZAdjuvant immunotherapy in resected non-small cell lung cancer harboring oncogenic driver alterations beyond EGFR and ALK: results from a retrospective analysishttps://www.pharmaradar360.com/article/bearing-the-burden-of-clinical-ethics-consultation-requests-roles-and-responses-4c90ebdec3a602e8Pharma Surgeen2026-07-26T00:00:00.000ZBearing the Burden of Clinical Ethics Consultation: Requests, Roles, and Responseshttps://www.pharmaradar360.com/article/influence-of-marital-status-on-clinical-outcomes-in-peripheral-t-cell-lymphoma-a-30d6035a1d2a06d9Pharma Surgeen2026-07-26T00:00:00.000ZInfluence of marital status on clinical outcomes in peripheral T-cell lymphoma: a population-based analysishttps://www.pharmaradar360.com/article/extranodal-involvement-defines-distinct-immune-molecular-phenotypes-and-clinical-f65211d041c2960dPharma Surgeen2026-07-26T00:00:00.000ZExtranodal involvement defines distinct immune-molecular phenotypes and clinical outcomes in diffuse large b-cell lymphomahttps://www.pharmaradar360.com/article/pan-cancer-analysis-identifies-kansl2-as-a-cell-cycle-associated-regulator-of-tu-f71721cb0545c2adPharma Surgeen2026-07-26T00:00:00.000ZPan-cancer analysis identifies KANSL2 as a cell-cycle–associated regulator of tumor progression and immunity in liver hepatocellular carcinomahttps://www.pharmaradar360.com/article/clinical-outcomes-at-6-months-after-mrgfus-thalamotomy-in-parkinson-s-disease-a-311880d1cc4702fbPharma Surgeen2026-07-26T00:00:00.000ZClinical outcomes at 6 months after MRgFUS thalamotomy in Parkinson’s disease: a large longitudinal cohort studyhttps://www.pharmaradar360.com/article/pregnancy-in-ctd-interstitial-lung-disease-current-evidence-clinical-challenges-5fd53cacb6680c56Pharma Surgeen2026-07-26T00:00:00.000ZPregnancy in CTD‐interstitial lung disease: Current evidence, clinical challenges, and a proposed management algorithmhttps://www.pharmaradar360.com/article/evaluation-of-the-reliability-of-current-neonatal-malnutrition-indicators-in-dia-d54b6aab40e54a77Pharma Surgeen2026-07-26T00:00:00.000ZEvaluation of the reliability of current neonatal malnutrition indicators in diagnosis: An analysis of a retrospective cohorthttps://www.pharmaradar360.com/article/lymphoplasmapheresis-for-refractory-anti-n-methyl-d-aspartate-receptor-encephali-6ecac61a89d85d54Pharma Surgeen2026-07-26T00:00:00.000ZLymphoplasmapheresis for Refractory Anti–N‐Methyl‐D‐Aspartate Receptor Encephalitis: A Case Reporthttps://www.pharmaradar360.com/article/the-efficacy-of-adjunctive-platelet-concentrates-in-combined-guided-tissue-regen-61750856ed87923fPharma Surgeen2026-07-26T00:00:00.000ZThe Efficacy of Adjunctive Platelet Concentrates in Combined Guided Tissue Regeneration and Bovine Bone Grafting for Intrabony Defects: A Systematic Reviewhttps://www.pharmaradar360.com/article/high-cell-density-cultivation-of-hek293-cells-using-a-2l-membrane-stirred-biorea-90f83e29876d9e24Pharma Surgeen2026-07-26T00:00:00.000ZHigh Cell Density Cultivation of HEK293 Cells Using a 2L Membrane‐Stirred Bioreactorhttps://www.pharmaradar360.com/article/inventory-replenishment-and-transshipment-for-distributed-autologous-cell-therap-f4fb2e79bef3ef0dPharma Surgeen2026-07-26T00:00:00.000ZInventory Replenishment and Transshipment for Distributed Autologous Cell Therapy Manufacturing Networkshttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-company-limited-revenue-breakdown-dus-3ky-3fe440e8d0750180Pharma Surgeen2026-07-25T23:30:38.000ZHansoh Pharmaceutical Group Company Limited Revenue Breakdown – DUS:3KYhttps://www.pharmaradar360.com/article/the-biotech-scientist-now-running-for-senate-ad362ff569b4253ePharma Surgeen2026-07-25T23:28:39.000ZThe Biotech Scientist Now Running for Senatehttps://www.pharmaradar360.com/article/legend-biotech-corp-legn-revenue-breakdown-business-segments-regional-revenue-pr-d35c0702a801fe33Pharma Surgeen2026-07-25T22:47:16.000ZLegend Biotech Corp (LEGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contributionhttps://www.pharmaradar360.com/article/price-to-book-forward-of-shanghai-xiao-fang-pharmaceutical-co-ltd-class-a-sse-60-87b3d16e4b38a74bPharma Surgeen2026-07-25T22:44:39.000ZPrice to book forward of Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A – SSE:603207https://www.pharmaradar360.com/article/what-do-moonlake-s-latest-week-40-hs-results-really-mean-for-investors-9f702ce2a4a5c8ffPharma Surgeen2026-07-25T22:38:55.000ZWhat Do MoonLake's Latest Week 40 HS Results Really Mean for Investorshttps://www.pharmaradar360.com/article/honz-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300086-408e3ac6f87e0d20Pharma Surgeen2026-07-25T22:22:21.000ZHonz Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:300086https://www.pharmaradar360.com/article/what-is-the-latest-on-capricor-therapeutics-deramiocel-and-its-fda-journey-0d25ded03b9c208ePharma Surgeen2026-07-25T22:15:52.000ZWhat is the latest on Capricor Therapeutics' Deramiocel and its FDA journeyhttps://www.pharmaradar360.com/article/why-is-mbx-biosciences-new-cbo-appointment-so-significant-for-investors-a0dabf324abde69dPharma Surgeen2026-07-25T21:28:58.000ZWhy is MBX Biosciences' new CBO appointment so significant for investorshttps://www.pharmaradar360.com/article/indrayani-biotech-ltd-revenue-breakdown-bse-indranib-4446814c6bf43246Pharma Surgeen2026-07-25T21:18:59.000ZIndrayani Biotech Ltd. Revenue Breakdown – BSE:INDRANIBhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-apeloa-pharmaceutical-co-ltd-class-a-szse-00-4bfc00dc297ce2a8Pharma Surgeen2026-07-25T21:12:30.000ZEnterprise value to EBIT forward of Apeloa Pharmaceutical Co. Ltd. Class A – SZSE:000739https://www.pharmaradar360.com/article/gc-biopharma-targets-300m-u-s-alglio-sales-expands-korea-led-biotech-push-chosun-fcb1e970c2f4ccf1Pharma Surgeen2026-07-25T21:01:00.000ZGC Biopharma targets $300m U.S. Alglio sales, expands Korea-led biotech push - CHOSUNBIZhttps://www.pharmaradar360.com/article/jiangsu-cowin-biotech-co-ltd-class-a-revenue-breakdown-sse-688426-c843837add15e8d1Pharma Surgeen2026-07-25T20:52:52.000ZJiangsu Cowin Biotech Co., Ltd. Class A Revenue Breakdown – SSE:688426https://www.pharmaradar360.com/article/price-to-earnings-forward-of-shanghai-xiao-fang-pharmaceutical-co-ltd-class-a-ss-ed4a255ab171d86fPharma Surgeen2026-07-25T20:45:16.000ZPrice to earnings forward of Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A – SSE:603207https://www.pharmaradar360.com/article/price-to-book-forward-of-hyundai-pharmaceutical-co-ltd-krx-004310-83e5edb93cd379f8Pharma Surgeen2026-07-25T20:29:16.000ZPrice to book forward of Hyundai Pharmaceutical Co., Ltd. – KRX:004310https://www.pharmaradar360.com/article/pbf9-etf-profile-dividends-returns-swb-pbf9-c2b8a03f6d606005Pharma Surgeen2026-07-25T20:26:29.000ZPBF9 ETF Profile: Dividends, Returns (SWB:PBF9)https://www.pharmaradar360.com/article/cai-lay-veterinary-pharmaceutical-jsc-revenue-breakdown-hnx-mkv-45919ef38fbf2c30Pharma Surgeen2026-07-25T20:25:08.000ZCai Lay Veterinary Pharmaceutical JSC Revenue Breakdown – HNX:MKVhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-sponsored-adr-revenue-breakdown-bx-tev-2137bfb473f15f00Pharma Surgeen2026-07-25T20:08:24.000ZTeva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEVhttps://www.pharmaradar360.com/article/fermenta-biotech-ltd-revenue-breakdown-bse-fermenta-136ae9cb29459889Pharma Surgeen2026-07-25T19:53:01.000ZFermenta Biotech Ltd Revenue Breakdown – BSE:FERMENTAhttps://www.pharmaradar360.com/article/purple-biotech-ltd-sponsored-adr-revenue-breakdown-mun-1yi0-f26880cb37cf1d14Pharma Surgeen2026-07-25T19:43:50.000ZPurple Biotech Ltd. Sponsored ADR Revenue Breakdown – MUN:1YI0https://www.pharmaradar360.com/article/has-ocugen-s-recent-convertible-notes-offering-stabilized-its-financial-future-24b60403ee69b13dPharma Surgeen2026-07-25T19:33:15.000ZHas Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Futurehttps://www.pharmaradar360.com/article/concord-biotech-ltd-revenue-breakdown-nse-concordbio-22534b5153202345Pharma Surgeen2026-07-25T19:33:14.000ZConcord Biotech Ltd. Revenue Breakdown – NSE:CONCORDBIOhttps://www.pharmaradar360.com/article/pbf9-etf-profile-dividends-returns-mun-pbf9-995de58ac329efb1Pharma Surgeen2026-07-25T19:32:00.000ZPBF9 ETF Profile: Dividends, Returns (MUN:PBF9)https://www.pharmaradar360.com/article/vrxa-veraxa-biotech-ag-ord-shs-price-1-800-chg-0-060-c61e5e0c5fa802bdPharma Surgeen2026-07-25T19:09:35.000ZVRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060https://www.pharmaradar360.com/article/etfs-investing-in-rtw-biotech-opportunities-ltd-usd-stocks-7acab5e94a8204a3Pharma Surgeen2026-07-25T19:06:04.000ZETFs Investing in RTW Biotech Opportunities Ltd USD Stockshttps://www.pharmaradar360.com/article/200-tariff-threat-on-us-generic-drug-imports-what-it-means-for-india-a6fb1a93cf90eca2Pharma Surgeen2026-07-25T19:04:27.000Z200% tariff threat on US generic drug imports: What it means for Indiahttps://www.pharmaradar360.com/article/pharmaceutical-team-explores-cooperation-with-uzbekistan-44c85f55194f810cPharma Surgeen2026-07-25T19:00:00.000ZPharmaceutical team explores cooperation with Uzbekistanhttps://www.pharmaradar360.com/article/ntla-stock-surges-35-overnight-retail-mood-peaks-ahead-of-first-ever-phase-3-rea-d5beb93535a18e5ePharma Surgeen2026-07-25T18:54:43.000ZNTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapyhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-cabio-biotech-wuhan-co-ltd-class-a-sse-688089-308065a9681f27d6Pharma Surgeen2026-07-25T18:46:12.000ZPrice to earnings forward of CABIO Biotech (Wuhan) Co. Ltd. Class A – SSE:688089https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-guizhou-bailing-group-pharmaceutical-co-l-7fff2283283da917Pharma Surgeen2026-07-25T18:45:00.000ZEnterprise value to revenue forward of Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A – SZSE:002424https://www.pharmaradar360.com/article/sichuan-huiyu-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-688553-f1296872bf57485cPharma Surgeen2026-07-25T18:41:00.000ZSichuan Huiyu Pharmaceutical Co. Ltd. Class A Revenue Breakdown – SSE:688553https://www.pharmaradar360.com/article/china-res-pharmaceutical-group-ltd-revenue-breakdown-otc-crpgf-899280fde39001adPharma Surgeen2026-07-25T18:40:03.000ZCHINA RES PHARMACEUTICAL GROUP LTD. Revenue Breakdown – OTC:CRPGFhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-shanghai-xiao-fang-pharmaceutical-co-ltd-c-77191c79639f5586Pharma Surgeen2026-07-25T18:15:42.000ZEnterprise value to EBITDA forward of Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A – SSE:603207https://www.pharmaradar360.com/article/sopan-pharmaceutical-ipo-analysis-sopan-pharmaceutical-ipo-new-ipo-opening-ipo-c-5c73c5eb1872d5f0Pharma Surgeen2026-07-25T18:07:20.000ZSopan Pharmaceutical Ipo Analysis | Sopan Pharmaceutical Ipo | New Ipo Opening | Ipo Conor Mcgregor (wkIR5koJkM)https://www.pharmaradar360.com/article/nbr-seeks-5yr-pharma-output-data-to-verify-vat-compliance-27a8932daaa853b4Pharma Surgeen2026-07-25T18:00:00.000ZNBR seeks 5yr pharma output data to verify VAT compliancehttps://www.pharmaradar360.com/article/sinovac-biotech-ltd-sva-revenue-breakdown-business-segments-regional-revenue-pro-a1467332027b86e3Pharma Surgeen2026-07-25T17:44:32.000ZSinovac Biotech Ltd (SVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contributionhttps://www.pharmaradar360.com/article/missed-ai-memory-bull-run-biotech-may-be-the-next-breakout-trade-but-retail-sent-671bce17695a553aPharma Surgeen2026-07-25T17:39:17.000ZMissed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lowerhttps://www.pharmaradar360.com/article/recursion-pharmaceuticals-stock-rxrx-opinions-on-trading-ranges-and-biotech-pros-5d22a844be00bf1ePharma Surgeen2026-07-25T17:33:00.000ZRecursion Pharmaceuticals Stock (RXRX) Opinions on Trading Ranges and Biotech Prospectshttps://www.pharmaradar360.com/article/diabetes-drug-may-help-repair-liver-damage-a83fc56205cf7eaaPharma Surgeen2026-07-25T17:24:25.000ZDiabetes drug may help repair liver damagehttps://www.pharmaradar360.com/article/etfs-investing-in-west-pharmaceutical-services-inc-stocks-6e8179f04a3ab403Pharma Surgeen2026-07-25T16:53:11.000ZETFs Investing in West Pharmaceutical Services, Inc. Stockshttps://www.pharmaradar360.com/article/protect-pharmaceutical-corp-revenue-breakdown-otc-prtt-603942ed1bba7526Pharma Surgeen2026-07-25T16:52:01.000ZProtect Pharmaceutical Corp Revenue Breakdown – OTC:PRTThttps://www.pharmaradar360.com/article/zhejiang-huahai-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-600521-1fb8a3f83bfd17eaPharma Surgeen2026-07-25T16:51:09.000ZZhejiang Huahai Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:600521https://www.pharmaradar360.com/article/cspc-pharmaceutical-group-limited-revenue-breakdown-ls-548183-1ee22c7a37ed95cdPharma Surgeen2026-07-25T16:30:41.000ZCSPC Pharmaceutical Group Limited Revenue Breakdown – LS:548183https://www.pharmaradar360.com/article/from-grant-to-phase-3-success-advancing-rare-sarcoma-research-conquer-cancer-99fb0fbce42e9e24Pharma Surgeen2026-07-25T16:20:39.000ZFrom Grant to Phase 3 Success: Advancing Rare Sarcoma Research – Conquer Cancerhttps://www.pharmaradar360.com/article/us-generic-drug-tariff-to-have-limited-near-term-impact-on-indian-firms-report-1a62bdf0c6c85f2fPharma Surgeen2026-07-25T16:08:46.000ZUS generic drug tariff to have limited near-term impact on Indian firms: Reporthttps://www.pharmaradar360.com/article/reyon-pharmaceutical-co-ltd-revenue-breakdown-krx-102460-d8b74db599fb2bb5Pharma Surgeen2026-07-25T15:49:24.000ZReyon Pharmaceutical Co., Ltd. Revenue Breakdown – KRX:102460https://www.pharmaradar360.com/article/murata-stock-and-2-japanese-shares-investors-are-watching-for-cash-flow-value-29f133474283b709Pharma Surgeen2026-07-25T15:24:54.000ZMurata Stock And 2 Japanese Shares Investors Are Watching For Cash Flow Valuehttps://www.pharmaradar360.com/article/price-to-sales-forward-of-shree-ganesh-biotech-india-ltd-bse-shreeganes-1863a137b3d165c6Pharma Surgeen2026-07-25T15:21:07.000ZPrice to sales forward of Shree Ganesh Biotech (India) Ltd. – BSE:SHREEGANEShttps://www.pharmaradar360.com/article/a-single-dose-reversed-autism-like-symptoms-in-adult-mice-within-hours-662cabf608e1e559Pharma Surgeen2026-07-25T15:09:37.000ZA single dose reversed autism-like symptoms in adult mice within hourshttps://www.pharmaradar360.com/article/eli-lilly-delays-fda-filing-for-next-generation-weight-loss-drug-retatrutide-4d47b3f5b8beef54Pharma Surgeen2026-07-25T15:01:14.000ZEli Lilly delays FDA filing for next-generation weight-loss drug retatrutidehttps://www.pharmaradar360.com/article/dcgi-gives-go-ahead-for-phase-iii-trial-of-zydus-desidustat-in-sickle-cell-disea-ba67adc268670735Pharma Surgeen2026-07-25T14:47:24.000ZDCGI Gives Go-Ahead for Phase III Trial of Zydus' Desidustat in Sickle Cell Diseasehttps://www.pharmaradar360.com/article/superagers-keep-youthful-memories-but-their-dna-does-not-explain-why-204138ece07ea6e6Pharma Surgeen2026-07-25T14:41:54.000ZSuperagers keep youthful memories but their DNA does not explain whyhttps://www.pharmaradar360.com/article/merck-unveils-early-global-access-plan-for-monthly-hiv-prevention-pill-ahead-of-5047f67ab361ada1Pharma Surgeen2026-07-25T14:37:31.000ZMerck unveils early global access plan for monthly HIV prevention pill ahead of phase 3 completionhttps://www.pharmaradar360.com/article/selinexor-for-myelofibrosis-or-a-drug-in-search-of-a-disease-562e0b3916c1e4c3Pharma Surgeen2026-07-25T14:32:05.000ZSelinexor for myelofibrosis or a drug in search of a disease?https://www.pharmaradar360.com/article/the-bull-case-for-takeda-pharmaceutical-tse-4502-could-change-following-new-zaso-f16f3d9afc486b16Pharma Surgeen2026-07-25T14:27:38.000ZThe Bull Case For Takeda Pharmaceutical (TSE:4502) Could Change Following New Zasocitinib Phase 3 Psoriasis Datahttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-beijing-sl-pharmaceutical-co-ltd-class-a-s-8e1e11525c8ae90aPharma Surgeen2026-07-25T14:18:35.000ZEnterprise value to EBITDA forward of Beijing SL Pharmaceutical Co. Ltd. Class A – SZSE:002038https://www.pharmaradar360.com/article/afghanistan-uzbekistan-pledge-to-bolster-healthcare-pharmaceutical-partnership-96c5e89a9d8853bePharma Surgeen2026-07-25T14:01:48.000ZAfghanistan, Uzbekistan Pledge to Bolster Healthcare & Pharmaceutical Partnershiphttps://www.pharmaradar360.com/article/what-just-happened-with-day-one-biopharmaceuticals-and-servier-417f07c6e2a98784Pharma Surgeen2026-07-25T13:37:01.000ZWhat Just Happened with Day One Biopharmaceuticals and Servierhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-shanghai-xiao-fang-pharmaceutical-co-ltd-class-a-sse-6-1bd0fdfc3df9547cPharma Surgeen2026-07-25T13:36:49.000ZPrice to sales forward of Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A – SSE:603207https://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678Pharma Surgeen2026-07-25T13:35:24.000Z14 New Weight Loss Drugshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-shanghai-xiao-fang-pharmaceutical-co-ltd-cla-0458da3bcb940b98Pharma Surgeen2026-07-25T13:32:52.000ZEnterprise value to EBIT forward of Shanghai Xiao Fang Pharmaceutical Co., Ltd. Class A – SSE:603207https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-shs-unsponsored-brazilian-depositary-receipt-repr-8b1371e3bb28ab3ePharma Surgeen2026-07-25T13:28:46.000ZUltragenyx Pharmaceutical Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Shhttps://www.pharmaradar360.com/article/is-arcturus-therapeutics-arct-032-a-game-changer-for-cystic-fibrosis-73f72f762479370bPharma Surgeen2026-07-25T13:18:06.000ZIs Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosishttps://www.pharmaradar360.com/article/commercial-trade-s-expanding-mandate-from-product-movement-to-commercial-perform-e92b28cf65a85178Pharma Surgeen2026-07-25T13:03:37.000ZCommercial Trade's Expanding Mandate: From Product Movement to Commercial Performancehttps://www.pharmaradar360.com/article/chinese-ambassador-to-zimbabwe-zhou-ding-visits-china-aided-zimbabwe-national-ph-c64612205e623697Pharma Surgeen2026-07-25T12:59:41.000ZChinese Ambassador to Zimbabwe, Zhou Ding, visits China-aided Zimbabwe National Pharmaceutical Warehousehttps://www.pharmaradar360.com/article/biotech-growth-trust-plc-revenue-breakdown-lse-biog-2fe9d5549f478ce2Pharma Surgeen2026-07-25T12:59:11.000ZBiotech Growth Trust PLC Revenue Breakdown – LSE:BIOGhttps://www.pharmaradar360.com/article/iran-india-agree-to-facilitate-medical-and-pharmaceutical-cooperation-at-brics-m-48352d9cbb78f6a0Pharma Surgeen2026-07-25T12:55:23.000ZIran, India agree to facilitate medical and pharmaceutical cooperation at BRICS meetinghttps://www.pharmaradar360.com/article/us-court-rules-fda-abortion-pill-restrictions-unlawful-orders-review-of-mifepris-be2f353462c2124ePharma Surgeen2026-07-25T12:44:26.000ZUS Court Rules FDA Abortion Pill Restrictions Unlawful, Orders Review of Mifepristone Ruleshttps://www.pharmaradar360.com/article/summit-therapeutics-reports-positive-phase-3-trial-data-for-ivonescimab-eadcb2db40960e8ePharma Surgeen2026-07-25T12:41:19.000ZSummit Therapeutics Reports Positive Phase 3 Trial Data for Ivonescimabhttps://www.pharmaradar360.com/article/fatty-liver-disease-scarring-improved-by-common-diabetes-drug-bfb52cf5e9ecd188Pharma Surgeen2026-07-25T12:27:20.000ZFatty liver disease scarring improved by common diabetes drughttps://www.pharmaradar360.com/article/what-drove-avoro-capital-advisors-strategic-exit-from-akero-therapeutics-c6e9ce9060367a5bPharma Surgeen2026-07-25T12:15:52.000ZWhat Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeuticshttps://www.pharmaradar360.com/article/argenx-a-biotech-powerhouse-poised-for-broad-expansion-58dc8f43049008f8Pharma Surgeen2026-07-25T12:11:12.000ZArgenx: A Biotech Powerhouse Poised for Broad Expansionhttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-usd-revenue-breakdown-lse-rtw-96561b961e553bc4Pharma Surgeen2026-07-25T12:08:05.000ZRTW Biotech Opportunities Ltd USD Revenue Breakdown – LSE:RTWhttps://www.pharmaradar360.com/article/a-grandfather-struggled-with-treatment-for-late-stage-pancreatic-cancer-until-a-08d951fc0bc86b3ePharma Surgeen2026-07-25T12:05:18.000ZA grandfather struggled with treatment for late-stage pancreatic cancer — until a clinical trial helped him beat the oddshttps://www.pharmaradar360.com/article/the-trump-administration-s-best-healthcare-idea-isn-t-the-one-getting-attention-81a296db8ec44463Pharma Surgeen2026-07-25T12:01:04.000ZThe Trump administration’s best healthcare idea isn’t the one getting attentionhttps://www.pharmaradar360.com/article/what-does-eric-green-s-retirement-mean-for-west-pharmaceutical-services-3097be13a03bbaf0Pharma Surgeen2026-07-25T11:56:16.000ZWhat Does Eric Green's Retirement Mean for West Pharmaceutical Serviceshttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-inc-bmrn-q1-2026-earnings-report-results-call-slides-c05de0dc10c853e9Pharma Surgeen2026-07-25T11:48:16.000ZBiomarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/what-s-driving-tenax-therapeutics-recent-surge-918d5a8082be5123Pharma Surgeen2026-07-25T11:47:56.000ZWhat's Driving Tenax Therapeutics' Recent Surgehttps://www.pharmaradar360.com/article/is-vaxcyte-s-vax-31-a-game-changer-in-the-vaccine-landscape-4c69cc5b1dee688aPharma Surgeen2026-07-25T11:43:38.000ZIs Vaxcyte's VAX-31 a Game-Changer in the Vaccine Landscapehttps://www.pharmaradar360.com/article/oral-glp-1-drugs-may-quiet-the-brain-s-food-craving-circuit-11c1fce8d3acbc92Pharma Surgeen2026-07-25T11:34:04.000ZOral GLP-1 drugs may quiet the brain’s food craving circuithttps://www.pharmaradar360.com/article/telcon-rf-pharmaceutical-inc-revenue-breakdown-krx-200230-830fcf79722373a5Pharma Surgeen2026-07-25T11:24:48.000ZTELCON RF PHARMACEUTICAL. Inc. Revenue Breakdown – KRX:200230https://www.pharmaradar360.com/article/why-is-cathie-wood-shifting-from-tech-to-biotech-3bcb0aaf97164e33Pharma Surgeen2026-07-25T11:08:39.000ZWhy is Cathie Wood Shifting from Tech to Biotechhttps://www.pharmaradar360.com/article/millions-could-access-cheaper-monthly-hiv-pill-under-new-merck-licensing-deal-17d9791f83d0f3ddPharma Surgeen2026-07-25T11:03:41.000ZMillions could access cheaper monthly HIV pill under new Merck licensing dealhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-q4-2025-earnings-report-results-call-slides-c38990fde942731cPharma Surgeen2026-07-25T10:55:44.000ZWest Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/west-pharmaceutical-stock-trades-steady-as-investors-digest-stronger-2025-guidan-d05a13f441af3983Pharma Surgeen2026-07-25T10:55:43.000ZWest Pharmaceutical stock trades steady as investors digest stronger 2025 guidance and recent marginhttps://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-07-25T10:54:30.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/6-things-to-know-about-india-s-first-dengue-vaccine-d97ff93e7ab14864Pharma Surgeen2026-07-25T10:40:40.000Z6 things to know about India’s first dengue vaccinehttps://www.pharmaradar360.com/article/does-teva-pharmaceutical-industries-nyse-teva-still-look-undervalued-after-a-260-c6e96463ffd05ae4Pharma Surgeen2026-07-25T10:39:41.000ZDoes Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run?https://www.pharmaradar360.com/article/does-teva-pharmaceutical-industries-nyse-teva-still-look-undervalued-after-a-260-71320e958e9cb0eePharma Surgeen2026-07-25T10:39:40.000ZDoes Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run?https://www.pharmaradar360.com/article/biomarin-pharmaceutical-inc-bmrn-dividends-stock-splits-historical-payouts-and-e-3fdf9636fb036719Pharma Surgeen2026-07-25T10:23:31.000ZBioMarin Pharmaceutical Inc (BMRN) Dividends & Stock Splits: Historical Payouts and Event Timelinehttps://www.pharmaradar360.com/article/fugitive-doctor-on-run-for-21-years-was-living-as-an-l-a-biotech-executive-43bea266d1a82f2aPharma Surgeen2026-07-25T10:14:53.000ZFugitive doctor on run for 21 years was living as an L.A. biotech executivehttps://www.pharmaradar360.com/article/185750-forecast-price-target-prediction-for-2027-861d61497e8c8664Pharma Surgeen2026-07-25T10:11:44.000Z185750 Forecast — Price Target — Prediction for 2027https://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-0rn3-q3-2025-earnings-report-results-call-slides-0a71a7cc12b0b7d4Pharma Surgeen2026-07-25T10:09:39.000ZTakeda Pharmaceutical Co Ltd (0RN3) Q3 2025 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/okyo-pharma-outlines-path-to-phase-3-neptune-trial-of-urcosimod-for-neuropathic-b54e55278c82f1cfPharma Surgeen2026-07-25T10:08:51.000ZOKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal painhttps://www.pharmaradar360.com/article/a-daily-fiber-supplement-reduced-knee-arthritis-pain-and-improved-strength-7428d902f74853b9Pharma Surgeen2026-07-25T10:01:05.000ZA daily fiber supplement reduced knee arthritis pain and improved strengthhttps://www.pharmaradar360.com/article/guanhao-biotech-co-ltd-class-a-revenue-breakdown-szse-300238-7c4c759b579c479dPharma Surgeen2026-07-25T09:57:41.000ZGuanhao Biotech Co., Ltd. Class A Revenue Breakdown – SZSE:300238https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-moleculin-biotech-inc-nasdaq-mbrx-6b46ae252e838a5bPharma Surgeen2026-07-25T09:56:02.000ZEnterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRXhttps://www.pharmaradar360.com/article/fubara-s-medical-industrial-revolution-rivers-rises-as-africa-s-next-pharmaceuti-40dc6bd8aedf8197Pharma Surgeen2026-07-25T09:34:11.000ZFubara’s Medical Industrial Revolution: Rivers rises as Africa’s next pharmaceutical hubhttps://www.pharmaradar360.com/article/us-listed-rare-disease-biotech-hit-with-full-clinical-hold-data-unblinding-ahead-420e6b8917890de5Pharma Surgeen2026-07-25T09:33:25.000ZUS-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Aheadhttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-nasdaq-bmrn-presents-a-high-quality-breakout-setup-with-485b81b6467a0cd3Pharma Surgeen2026-07-25T09:30:52.000ZBioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratingshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-jinling-pharmaceutical-co-ltd-class-a-szse-000919-93c569d367608477Pharma Surgeen2026-07-25T09:28:14.000ZPrice to sales forward of Jinling Pharmaceutical Co., Ltd. Class A – SZSE:000919https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jinling-pharmaceutical-co-ltd-class-a-szse-e374e4783148d8cfPharma Surgeen2026-07-25T09:26:44.000ZEnterprise value to EBITDA forward of Jinling Pharmaceutical Co., Ltd. Class A – SZSE:000919https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-shares-sold-by-kbc-group-nv-0792231d4a086ec1Pharma Surgeen2026-07-25T09:17:44.000ZWest Pharmaceutical Services, Inc. $WST Shares Sold by KBC Group NVhttps://www.pharmaradar360.com/article/tonghua-golden-horse-pharmaceutical-industry-co-ltd-class-a-revenue-breakdown-sz-a22d5da90167d9b0Pharma Surgeen2026-07-25T08:50:34.000ZTonghua Golden-Horse Pharmaceutical Industry Co. Ltd. Class A Revenue Breakdown – SZSE:000766https://www.pharmaradar360.com/article/veraxa-biotech-shareholders-approve-governance-changes-by-investing-com-ceff30ab5c0bd72cPharma Surgeen2026-07-25T08:47:43.000ZVeraxa Biotech shareholders approve governance changes By Investing.comhttps://www.pharmaradar360.com/article/pharmagreen-biotech-inc-revenue-breakdown-otc-phbi-3bc9b4995a29101aPharma Surgeen2026-07-25T08:41:50.000ZPharmagreen Biotech Inc. Revenue Breakdown – OTC:PHBIhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-07-25T08:27:42.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/epoch-investment-partners-inc-acquires-39-745-shares-of-west-pharmaceutical-serv-8ebbaa0d4b163f04Pharma Surgeen2026-07-25T08:26:45.000ZEpoch Investment Partners Inc. Acquires 39,745 Shares of West Pharmaceutical Services, Inc. $WSThttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-a-bargain-after-7-7-d-2b3c898e4e24ba43Pharma Surgeen2026-07-25T08:26:15.000ZIs West Pharmaceutical Services Inc (WST) a Bargain After 7.7% Dhttps://www.pharmaradar360.com/article/shaanxi-panlong-pharmaceutical-group-co-ltd-class-a-revenue-breakdown-szse-00286-d117702eb0ee2cc6Pharma Surgeen2026-07-25T08:24:01.000ZShaanxi Panlong Pharmaceutical Group Co., Ltd. Class A Revenue Breakdown – SZSE:002864https://www.pharmaradar360.com/article/kintor-pharmaceutical-ltd-revenue-breakdown-hkex-9939-a66572cf0d4d6649Pharma Surgeen2026-07-25T08:17:57.000ZKintor Pharmaceutical Ltd Revenue Breakdown – HKEX:9939https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-wst-q1-2026-earnings-report-results-call-slides-ead0e9b082437a70Pharma Surgeen2026-07-25T07:48:32.000ZWest Pharmaceutical Services, Inc. (WST) Q1 2026 Earnings Report - Results, Call & Slideshttps://www.pharmaradar360.com/article/wakamoto-pharmaceutical-co-ltd-revenue-breakdown-tse-4512-01956d2bf2ef54f3Pharma Surgeen2026-07-25T07:44:33.000ZWakamoto Pharmaceutical Co., Ltd. Revenue Breakdown – TSE:4512https://www.pharmaradar360.com/article/covaxin-phase-3-drug-trial-approved-by-sec-af4b5970a0d3cedbPharma Surgeen2026-07-25T07:26:59.000ZCovaxin phase 3 drug trial approved by SEChttps://www.pharmaradar360.com/article/sommarenkat-jenny-nilsson-skadespelare-strosa-i-charmiga-gamla-stan-bc1b2f8429766ba7Pharma Surgeen2026-07-25T07:23:47.000ZSommarenkät: Jenny Nilsson, skådespelare – Strosa i charmiga gamla stanhttps://www.pharmaradar360.com/article/video-254-exciting-news-apitegromab-phase-3-trial-updates-bob-dnmst6vtzo-e0c0c8abbf51a793Pharma Surgeen2026-07-25T07:02:20.000ZVideo #254 - EXCITING NEWS - Apitegromab Phase 3 Trial Updates Bob (dNmSt6vtZo)https://www.pharmaradar360.com/article/cabio-biotech-wuhan-co-ltd-class-a-revenue-breakdown-sse-688089-f3091d9ed203ece4Pharma Surgeen2026-07-25T06:53:03.000ZCABIO Biotech (Wuhan) Co. Ltd. Class A Revenue Breakdown – SSE:688089https://www.pharmaradar360.com/article/fda-approves-lytenava-first-ophthalmic-bevacizumab-for-wet-amd-07cd2bf7b7a85cfdPharma Surgeen2026-07-25T06:50:50.000ZFDA Approves LYTENAVA, First Ophthalmic Bevacizumab for Wet AMDhttps://www.pharmaradar360.com/article/chmp-recommends-marketing-authorization-for-obicetrapib-in-eu-dfad413ce3b9cf8bPharma Surgeen2026-07-25T06:50:50.000ZCHMP Recommends Marketing Authorization for Obicetrapib in EUhttps://www.pharmaradar360.com/article/chongqing-lummy-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300006-641c1afd34535d5dPharma Surgeen2026-07-25T06:46:28.000ZChongqing Lummy Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:300006https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-cardiac-biotech-solutions-inc-otc-cbsc-b2a828ab53737672Pharma Surgeen2026-07-25T06:41:20.000ZEnterprise value to EBIT forward of Cardiac Biotech Solutions Inc. – OTC:CBSChttps://www.pharmaradar360.com/article/greek-hospital-drug-funding-crisis-pharma-sector-warns-on-patient-access-6a15773e0daa8251Pharma Surgeen2026-07-25T06:34:11.000ZGreek hospital drug funding crisis, pharma sector warns on patient accesshttps://www.pharmaradar360.com/article/participant-screening-begins-for-phase-2-study-of-novel-osa-therapy-47baaca35dd127f0Pharma Surgeen2026-07-25T06:26:30.000ZParticipant Screening Begins for Phase 2 Study of Novel OSA Therapyhttps://www.pharmaradar360.com/article/draper-to-set-up-venture-capital-firm-in-busan-to-invest-in-k-content-physical-a-a116ed7357064792Pharma Surgeen2026-07-25T05:31:00.000ZDraper to Set Up Venture Capital Firm in Busan to Invest in K-Content, Physical AI, Biotech and Blockchainhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-lushang-freda-pharmaceutical-co-ltd-class-1085fea9124a6fddPharma Surgeen2026-07-25T05:22:54.000ZEnterprise value to revenue forward of Lushang Freda Pharmaceutical Co., Ltd. Class A – SSE:600223https://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-us-will-release-its-earnings-report-on-july-30-fb8a2164d1d70016Pharma Surgeen2026-07-25T05:13:03.000ZTakeda Pharmaceutical (TAK.US) will release its earnings report on July 30.https://www.pharmaradar360.com/article/what-just-happened-to-ocular-therapeutix-stock-a57bb1b8ad477564Pharma Surgeen2026-07-25T04:36:57.000ZWhat Just Happened to Ocular Therapeutix Stockhttps://www.pharmaradar360.com/article/fda-panel-gives-nod-to-six-controversial-peptides-f02d20943de4c6aaPharma Surgeen2026-07-25T04:33:14.000ZFDA panel gives nod to six controversial peptideshttps://www.pharmaradar360.com/article/samjin-pharmaceutical-co-ltd-revenue-breakdown-krx-005500-dd62c7080ca42147Pharma Surgeen2026-07-25T04:31:15.000ZSamjin Pharmaceutical Co., Ltd. Revenue Breakdown – KRX:005500https://www.pharmaradar360.com/article/u-s-ipo-weekly-recap-crispr-biotech-pops-44-as-more-names-join-the-ipo-pipeline-98c60f17476a8d94Pharma Surgeen2026-07-25T04:30:00.000ZU.S. IPO Weekly Recap: CRISPR Biotech Pops 44% As More Names Join The IPO Pipelinehttps://www.pharmaradar360.com/article/wegovy-vs-mounjaro-8-important-differences-ff95a7e838063543Pharma Surgeen2026-07-25T04:23:21.000ZWegovy vs. Mounjaro: 8 Important Differenceshttps://www.pharmaradar360.com/article/bicara-s-cancer-drug-enters-crucial-trial-phase-says-ceo-claire-mazumdar-504e20a964248910Pharma Surgeen2026-07-25T03:41:54.000ZBicara’s cancer drug enters crucial trial phase, says CEO Claire Mazumdarhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-biotech-growth-trust-plc-turquoise-biogl-28a9cbf07c1bf563Pharma Surgeen2026-07-25T03:39:41.000ZEnterprise value to revenue forward of Biotech Growth Trust PLC – TURQUOISE:BIOGLhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-sees-margin-improvement-narrative-backed-e52ce20734007004Pharma Surgeen2026-07-25T03:38:58.000ZWest Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Resultshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-stock-sees-margin-improvement-narrative-backed-b56c0ea206934abePharma Surgeen2026-07-25T03:38:57.000ZWest Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Resultshttps://www.pharmaradar360.com/article/chugai-pharmaceutical-chgcf-reports-strong-first-half-earnings-a95d97db44dffa89Pharma Surgeen2026-07-25T03:33:45.000ZChugai Pharmaceutical (CHGCF) Reports Strong First Half Earningshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-revenue-breakdown-otc-tkphf-5b1e3032af4af548Pharma Surgeen2026-07-25T03:32:58.000ZTakeda Pharmaceutical Co., Ltd. Revenue Breakdown – OTC:TKPHFhttps://www.pharmaradar360.com/article/krystal-biotech-inc-revenue-breakdown-nasdaq-krys-b656b361399351c4Pharma Surgeen2026-07-25T03:23:23.000ZKrystal Biotech, Inc. Revenue Breakdown – NASDAQ:KRYShttps://www.pharmaradar360.com/article/jiangxi-synergy-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300636-61e51cf9a5e886f8Pharma Surgeen2026-07-25T03:11:26.000ZJiangxi Synergy Pharmaceutical Co. Ltd. Class A Revenue Breakdown – SZSE:300636https://www.pharmaradar360.com/article/celcuity-s-gedatolisib-regulatory-win-meets-commercial-reality-42741420b58624c1Pharma Surgeen2026-07-25T03:10:53.000ZCelcuity's Gedatolisib: Regulatory Win Meets Commercial Realityhttps://www.pharmaradar360.com/article/gene-editing-biotech-scribe-jumps-44-in-market-debut-targets-heart-disease-1b24b3e8635ebe30Pharma Surgeen2026-07-25T02:45:00.000ZGene-Editing Biotech Scribe Jumps 44% in Market Debut, Targets Heart Diseasehttps://www.pharmaradar360.com/article/retatrutide-for-weight-loss-availability-dosage-and-more-9de68bf24030fa2bPharma Surgeen2026-07-25T02:38:43.000ZRetatrutide for Weight Loss: Availability, Dosage, and Morehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-medicofarma-biotech-spolka-akcyjna-newconnec-c69dc2d0742c246bPharma Surgeen2026-07-25T02:09:54.000ZEnterprise value to EBIT forward of Medicofarma Biotech Spolka Akcyjna – NEWCONNECT:MDBhttps://www.pharmaradar360.com/article/beijing-beilu-pharmaceutical-co-ltd-class-a-revenue-breakdown-szse-300016-a1c23937b621a7b7Pharma Surgeen2026-07-25T02:07:46.000ZBeijing Beilu Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SZSE:300016https://www.pharmaradar360.com/article/veraxa-biotech-ag-nasdaq-vrxa-appoints-christoph-erkel-as-chief-scientific-offic-a810c5e9b7181078Pharma Surgeen2026-07-25T02:04:00.000ZVERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officerhttps://www.pharmaradar360.com/article/what-does-blackrock-s-reduced-stake-in-orion-corporation-signify-316b3d131cfe6a4bPharma Surgeen2026-07-25T01:57:20.000ZWhat Does BlackRock's Reduced Stake in Orion Corporation Signifyhttps://www.pharmaradar360.com/article/this-week-in-boomtown-aviation-industry-in-ohio-affordable-housing-future-of-bio-51d5297eeb42b45bPharma Surgeen2026-07-25T01:39:00.000ZThis Week in Boomtown: Aviation industry in Ohio; affordable housing; future of biotechhttps://www.pharmaradar360.com/article/proprietary-biobotanical-microemulsion-technologies-c3b98d4fa2412c22Pharma Surgeen2026-07-25T01:33:50.000ZProprietary Biobotanical Microemulsion Technologieshttps://www.pharmaradar360.com/article/a215380-static-price-chart-kolmar-biotech-inc-kr7215380007-71c724dfe5eec533Pharma Surgeen2026-07-25T01:11:43.000ZA215380: Static price chart | Kolmar BioTech, Inc. | KR7215380007https://www.pharmaradar360.com/article/kolmar-biotech-inc-shareholders-board-members-managers-and-company-profile-kr721-a5992804a39b6a4aPharma Surgeen2026-07-25T01:11:43.000ZKolmar BioTech, Inc.: Shareholders Board Members Managers and Company Profile | KR7215380007https://www.pharmaradar360.com/article/west-pharmaceutical-services-i-wst-stock-forecasts-8708d5e13e78258bPharma Surgeen2026-07-25T00:53:12.000ZWest Pharmaceutical Services, I (WST) Stock Forecastshttps://www.pharmaradar360.com/article/stifel-reiterates-mirum-pharmaceuticals-stock-rating-after-rival-trial-fails-81e24ae1bdfed904Pharma Surgeen2026-07-25T00:16:21.000ZStifel reiterates Mirum Pharmaceuticals stock rating after rival trial failshttps://www.pharmaradar360.com/article/catering-417dea081ecb4e00Pharma Surgeen2026-07-25T00:00:00.000Zcateringhttps://www.pharmaradar360.com/article/spatiotemporal-multi-omics-reveals-lineage-spatial-and-functional-heterogeneity-e84924ea04f571e9Pharma Surgeen2026-07-25T00:00:00.000ZSpatiotemporal multi-omics reveals lineage, spatial and functional heterogeneity of tumor-associated macrophages and therapeutic vulnerabilities in the tumor microenvironmenthttps://www.pharmaradar360.com/article/comparison-of-whole-genome-sequencing-with-clinical-targeted-panel-sequencing-of-cc282f8d705f195bPharma Surgeen2026-07-25T00:00:00.000ZComparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world datahttps://www.pharmaradar360.com/article/prediction-of-single-cell-expression-from-low-plex-immunofluorescence-images-for-8c32e0fa2a82bb6ePharma Surgeen2026-07-25T00:00:00.000ZPrediction of single cell expression from low-plex immunofluorescence images for guiding precision oncologyhttps://www.pharmaradar360.com/article/understanding-public-perspectives-on-direct-to-consumer-pharmacogenomic-testing-7f4d2f18346bbc6fPharma Surgeen2026-07-25T00:00:00.000ZUnderstanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative studyhttps://www.pharmaradar360.com/article/25-69-27f176915ad196dePharma Surgeen2026-07-25T00:00:00.000Z25 ก.ค. 69อย. กำชับผู้ประกอบการใช้วัตถุเจือปนอาหารที่มีไนไตรท์ให้ถูกต้อง ตรวจเข้มสถานที่ผลิตอาหารกลุ่มเสี่ยง พร้อมเผยแพร่สื่อแนะนำการใช้อ่านเพิ่มเติม →https://www.pharmaradar360.com/article/full-blood-count-platelet-parameters-in-sickle-cell-disease-a-systematic-review-051bc648df07158dPharma Surgeen2026-07-25T00:00:00.000ZFull Blood Count Platelet Parameters in Sickle Cell Disease: A Systematic Review of Thrombocytosis, Thrombocytopenia, and Clinical Implicationshttps://www.pharmaradar360.com/article/quality-of-inpatient-clinical-documentation-a-bed-head-ticket-audit-at-a-tertiar-409bfbd535aae580Pharma Surgeen2026-07-25T00:00:00.000ZQuality of Inpatient Clinical Documentation: A Bed Head Ticket Audit at a Tertiary Care Hospital in Sri Lankahttps://www.pharmaradar360.com/article/clinical-drivers-of-cesarean-sections-during-the-covid-19-pandemic-a-robson-clas-f9e03364fa31dd6bPharma Surgeen2026-07-25T00:00:00.000ZClinical Drivers of Cesarean Sections During the COVID-19 Pandemic: A Robson Classification-Based Multivariable Analysishttps://www.pharmaradar360.com/article/platelet-concentrates-in-periodontal-regeneration-a-review-of-current-evidence-a-d357326aa0fbda83Pharma Surgeen2026-07-25T00:00:00.000ZPlatelet Concentrates in Periodontal Regeneration: A Review of Current Evidence and Clinical Perspectiveshttps://www.pharmaradar360.com/article/lt-b-gt-artificial-intelligence-in-admet-prediction-transforming-drug-safety-and-b4365db89883d392Pharma Surgeen2026-07-25T00:00:00.000Z&lt;b&gt;Artificial Intelligence in ADMET Prediction: Transforming Drug Safety and Pharmacokinetic Assessment &lt;/b&gt;https://www.pharmaradar360.com/article/virtual-reality-based-rehabilitation-versus-conventional-physiotherapy-for-impro-7352e2d99c19f50dPharma Surgeen2026-07-25T00:00:00.000ZVirtual Reality-Based Rehabilitation versus Conventional Physiotherapy for Improving Balance, Functional Mobility, and Fall Risk in Parkinson's Disease: A Randomized Controlled Trial